Testing a new anti-cancer drug in advanced cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early Phase 1 study tests OT-A201 (a first-time-in-humans drug) in people with certain relapsed or advanced cancers. It helps doctors learn the safest dose and how the treatment may work for cancers that have already been treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed (by biopsy or cytology) and either relapsed blood cancer or an advanced/metastatic solid tumor
- Your cancer must have measurable signs doctors can track on scans or tests
- You must have tried all standard available treatments for your cancer (or none are left)
- You must be able to do a baseline tissue sample (biopsy or bone marrow aspiration) if one isn’t available from a recent treatment
- Your general function should be pretty good (ECOG 0–1) and your life expectancy should be more than 3 months
- Your recent bloodwork and other lab tests must be acceptable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
This Phase 1 trial tests a new medicine (ABOD2011) in people with advanced solid tumors that have come back or spread after standard treatment. It may help by shrinking tumors and allows researchers to study the tumor by giving medicine directly into it and taking a biopsy.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
This trial tests a new drug, AWT020, for people with advanced cancer (solid tumors or lymphoma) that hasn't responded to other treatments. The goal is to see if it is safe and how well it works.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.